Objective: Accurate detection of anaplastic lymphoma kinase (ALK) rearrangement is crucial for ALK inhibitor (ALK-TKI) targeted therapy in non-small cell lung cancer (NSCLC) patients. Currently, the methods used in hospital laboratories include reverse transcription PCR (RT-PCR), fluorescence in situ hybridization (FISH), and the next generation sequencing (NGS). In this study, we evaluated the performance of the three methods in detecting ALK rearrangements to provide theoretical support for precise diagnosis of ALK. Methods: This study selected 38 ALK-positive patients and used RT-PCR, FISH, and NGS to detect ALK rearrangements in the samples. The consistency of the three methods in ALK detection was evaluated. Then, the consistency between these three ALK methods and the therapeutic effects of ALK-TKI will be analyzed separately. Results: The positive rates of ALK rearrangement detected by RT-PCR, FISH, and NGS were 89.47%, 86.84%, and 97.37%, respectively, among the 38 cases. Among them, NGS detected 3 rare ALK rearrangements. The consistency of RT-PCR and FISH in detecting ALK rearrangement was strong (Kappa=0.623, P＜0.05). However, there was no consistency between NGS and RT-PCR or FISH in detecting ALK rearrangement (Kappa=-0.044 and 0.303). The survival numbers of ALK-positive cases defined by the three methods after 22 months of ALK-TKI treatment were statistically analyzed, and the results showed no significant difference (P＞0.05). Conclusion: Compared with RT-PCR and FISH, the NGS method shows a higher positive detection rate, especially in rare ALK rearrangements, where it has a stronger detection capability. Therefore, this study advocates the use of NGS to detect ALK rearrangements when the experimental conditions are met, which can effectively improve the treatment outcome and prognosis assessment of NSCLC patients.
YUE Lin
,
BAI Xuefeng
,
XIANG Pengcheng
,
YU Fei
,
BAI Jianhui
,
FENG Liwen
,
GAO Yang
,
WU Xiaoyan
,
LIU En
,
DING Haimai
,
WANG Yanhong
. A comparative study of NGS, RT-PCR, and FISH for ALK detection in non-small cell lung cancer[J]. Journal of Baotou Medical College, 2025
, 41(10)
: 71
-76
.
DOI: 10.16833/j.cnki.jbmc.2025.10.014
[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China,2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[2] Arrieta O, Ramírez‐Tirado LA, Caballé‐Perez E, et al. Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR,ALK and KRAS mutation status[J]. Thorac Cancer, 2020, 11(4): 1026-1037.
[3] Mok T, Peters S, Camidge DR, et al. Outcomes according to ALK status determined by central IHC or FISH in patients with ALK-positive NSCLC enrolled in the phase Ⅲ ALEX study[J]. J Thorac Oncol, 2020, 1556: 30815-30817.
[4] Fukuda A, Yoshida T. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure[J]. Expert Rev Anticancer Ther, 2023, 23(11): 1157-1167.
[5] Kuang Y, Xu P, Wang J, et al. Detecting ALK rearrangement with RT-PCR: a reliable approach compared with next-generation sequencing in patients with NSCLC[J]. Mol Diagn Ther, 2021, 25(4): 487-494.
[6] Batra U, Nathany S, Sharma M, et al. IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered[J]. J Clin Pathol, 2022, 75(6): 405-409.
[7] Wang B, Chen R, Wang C, et al. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry/RT-PCR discordant NSCLC patients[J]. Hum Pathol, 2021, 114: 90-98.
[8] Cornelissen R, Dubbink HJ, von der Thüsen JH. ALK in Mesothelioma: to FISH or Not to FISH[J]. J Thorac Oncol, 2020, 15(10): e168-e169.
[9] Noé J, Bordogna W, Archer V, et al. Concordance between tissue ALK detection by immunohistochemistry and plasma ALK detection by next-generation sequencing in the randomized phase 3 ALEX study in patients with treatment-naive advanced ALK-positive NSCLC[J]. JTO Clin Res Rep, 2022, 3(7): 100341.
[10] Hu T, Chitnis N, Monos D, et al. Next-generation sequencing technologies: an overview[J]. Hum Immunol, 2021, 82(11): 801-811.
[11] Letovanec I, Finn S, Zygoura P, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the european thoracic oncology platform lungscape project[J]. J Thorac Oncol, 2018, 13(3): 413-425.
[12] Kuang Y, Xu P, Wang J, et al. Detecting ALK rearrangement with RT-PCR: a reliable approach compared with next-generation sequencing in patients with NSCLC[J]. Mol Diagn Ther, 2021, 25(4): 487-494.
[13] Du X, Zhang J, Gao H, et al. A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients[J]. Thorac Cancer, 2021, 12(20): 2773-2779.
